Alzamend Neuro (ALZN) Stock Price, News & Analysis

Company Overview

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Key Stats

• Today's Range: $1.17 to $1.22
• 50-Day Range: $1.11 to $1.46
• 52-Week Range: $1.06 to $15.06
• Volume: 76,220 shs
• Average Volume: 97,202 shs
• Market Capitalization: $6.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.00
• Consensus Rating: Buy

Alzamend Neuro Stock Analysis - MarketRank™

Alzamend Neuro scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Alzamend Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alzamend Neuro has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Alzamend Neuro are expected to decrease in the coming year, from ($1.68) to ($1.71) per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.62% of the float of Alzamend Neuro has been sold short.

Short Interest Ratio / Days to Cover

Alzamend Neuro has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alzamend Neuro has recently decreased by 48.81%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alzamend Neuro does not currently pay a dividend.

Dividend Growth

Alzamend Neuro does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.62% of the float of Alzamend Neuro has been sold short.

Short Interest Ratio / Days to Cover

Alzamend Neuro has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alzamend Neuro has recently decreased by 48.81%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Alzamend Neuro this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alzamend Neuro insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.55% of the stock of Alzamend Neuro is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

49.61% of the stock of Alzamend Neuro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALZN Stock Analysis - Frequently Asked Questions

How have ALZN shares performed this year?

Alzamend Neuro's stock was trading at $1.16 on January 1st, 2025. Since then, ALZN stock has increased by 1.7% and is now trading at $1.18.
View the best growth stocks for 2025 here.

How were Alzamend Neuro's earnings last quarter?

Alzamend Neuro, Inc. (NASDAQ:ALZN) posted its quarterly earnings data on Wednesday, December, 11th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($2.38) by $1.98.

When did Alzamend Neuro's stock split?

Alzamend Neuro shares reverse split before market open on Tuesday, July 16th 2024. The 1-10 reverse split was announced on Tuesday, July 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Alzamend Neuro IPO?

Alzamend Neuro (ALZN) raised $12 million in an initial public offering on Tuesday, June 15th 2021. The company issued 2,500,000 shares at $5.00 per share. Spartan Capital Securities, LLC served as the underwriter for the IPO and -- was co-manager.

How do I buy shares of Alzamend Neuro?

Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alzamend Neuro own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alzamend Neuro investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), Predictive Oncology (POAI), AST SpaceMobile (ASTS), NIO (NIO) and Ford Motor (F).

Company Calendar

• Last Earnings: 12/11/2024
• Today: 1/22/2025
• Next Earnings (Estimated): 3/24/2025
• Fiscal Year End: 4/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALZN
• CUSIP: N/A
• CIK: 1677077
• Web: www.alzamend.com
• Phone: 844-722-6303
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $32.00
• High Stock Price Target: $32.00
• Low Stock Price Target: $32.00
• Potential Upside/Downside: +2,611.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,950,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -289.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.80
• Quick Ratio: 3.80

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.52) per share
• Price / Book: -0.34

Miscellaneous

• Outstanding Shares: 5,430,000
• Free Float: 4,860,000
• Market Cap: $6.41 million
• Optionable: No Data
• Beta: -0.06